The gene therapy CDMO market size is expected to grow from US$ 2.60 billion in 2025 to US$ 14.17 billion by 2034; it is projected to register a CAGR of 20.3% during 2026-2034.

The increasing prevalence of chronic and genetic diseases, surging regulatory approvals and commercialization, and growing popularity of outsourcing gene therapy manufacturing by companies are noteworthy factors contributing to the expansion of the gene therapy CDMO market size. Additionally, the growing demand for personalized and rare disease therapies are projected to bring new gene therapy CDMO market trends in the near future.

The market experiences a transformation because automation and digitalization bring better efficiency and scalability and improved quality control. The technologies solve complex challenges which arise from developing personalized therapies because they minimize the need for human participation while they streamline the procedures which handle viral vector production and cell expansion. CDMOs implement process analytical technologies to monitor their operations in real time which allows them to adjust their processing methods while maintaining simultaneous production of multiple items. Digital twins use their predictive capabilities to forecast how cells will react under different testing conditions, which helps to improve factory processes. The combination of Sartorius's MODDE software with Ambr 15 bioreactors demonstrates how digital twin technology enables optimization through virtual twin systems. The process of viral vector optimization achieved a significant reduction in experimental duration to three weeks from eight weeks while it generated a tenfold rise in infectious titer through precise adjustment of pH and cell density parameters.

The use of machine learning algorithms together with predictive capabilities enables CDMOs to implement proactive measures which decrease operational interruptions while enhancing the therapeutic product quality and quantity. In October 2024, OmniaBio opened its new commercial-ready manufacturing facility and AI center of excellence in Hamilton, Ontario, Canada. The facility which covers 100,000 square feet stands among the biggest CDMOs which focus on manufacturing cell and gene therapies.

The regulatory requirements for gene therapy manufacturing necessitate organizations to collect and analyze extensive data throughout their manufacturing processes. AI and digital tools enable seamless data integration, ensuring that all necessary documentation is complete and accurate for regulatory review. CDMOs that use AI together with digital platforms can effectively handle the complex nature of regulatory submission processes while they maintain compliance with changing industry requirements.

Automation together with artificial intelligence and digital analytics systems has become the key approach for CDMOs to achieve operational efficiency through their implementation, thereby emerging as a significant trend in the gene therapy CDMO market.

End User-Based Insights

Based on end user, the gene therapy CDMO market is segmented into pharmaceutical companies, biopharmaceutical companies, and other end users. The biopharmaceutical companies segment held the largest gene therapy CDMO market share in 2025. The gene therapy CDMO market is mainly controlled by biopharmaceutical companies which include small biotech firms and startup companies that need outside help for their product development and manufacturing activities. The company's expansion results from its incomplete internal capacity combined with expensive research and development expenses and the difficult nature of gene therapy treatments which need special medical facilities and expert technical knowledge that the company usually does not possess. The company uses outsourcing to improve its clinical pipeline development process while maintaining its budget for research and development activities. The expanding gene therapy pipeline, with thousands of assets in development, creates increasing demand as biotechs require trustworthy partners for their needs in viral vector production and process optimization and GMP manufacturing services. Key examples include collaborations with leading CDMOs like Lonza and Catalent which support numerous biotech programs in oncology and rare diseases. Gilead Sciences (via Kite Pharma) and Amgen have also used CDMO services for their advanced development of gene-modified therapies. The biotechs use CDMO services to overcome their regulatory challenges which enables them to bring products to market faster, thereby fueling the gene therapy CDMO market growth.

The World Health Organization and Australian Institute of Health and Welfare are among the primary and secondary sources referred to while preparing the gene therapy CDMO market report.